Skip to main content
Premium Trial:

Request an Annual Quote

Exosome Diagnostics, Life Technologies Ink Agreement for Oncology Dx Program

NEW YORK (GenomeWeb News) – Exosome Diagnostics today said that it has signed an agreement with Life Technologies to use the Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument for its exosome biofluid in vitro diagnostics program.

Exosome will validate the 7500 platform with exosome biofluid RNA isolation kits in clinical trials beginning this year in brain and prostate cancer. Terms of the alliance were not disclosed.

New York-based Exosome is developing urine- and blood-based molecular diagnostic kits for cancer detection and monitoring. It is partnering with manufacturers to provide branded, OEM diagnostic instruments for regulatory approval and use in its CLIA-certified lab, it said.

"Our product development strategy is to match our exosome-based diagnostics technology with the most technically appropriate and widely accepted platforms available," Exosome Diagnostics COO David Okrongly said in a statement. "The ABI 7500 Fast Dx Real-Time PCR Instrument from Life Technologies combines state of the art quantitative PCR technology with broad market and regulatory acceptance, enabling physicians and laboratory customers to efficiently and accurately access diagnostic results."